医学
前列腺癌
镭-223
四分位间距
前列腺特异性抗原
内科学
回顾性队列研究
总体生存率
骨转移
癌症
肿瘤科
泌尿科
作者
Daichi Sasaki,Shingo Hatakeyama,Hideo Kawaguchi,Yoshiomi Hatayama,Yutaka Ishibashi,Ayumu Kusaka,Daisuke Noro,Toshikazu Tanaka,Hiroyuki Ito,Yoshiharu Okuyama,Teppei Okamoto,Hayato Yamamoto,Takahiro Yoneyama,Yasuhiro Hashimoto,Masahiko Aoki,Chikara Οhyama
标识
DOI:10.1016/j.urolonc.2021.11.005
摘要
To evaluate the effect of 6-cycle completion and earlier use of radium-233 dichloride (Ra223) on the prognosis of patients with metastatic castration-resistant prostate cancer (mCRPC).We retrospectively evaluated 75 patients with bone metastases-predominant mCRPC who were treated with Ra223 between August 2016 and August 2021. The primary purpose of the study was to assess the effect of Ra223 completion (6 cycles) on patient prognosis, and the secondary purpose was to investigate factors associated with Ra223 incompletion (fewer than 6 cycles) and overall survival.The median age of the patients was 72 years. The median number of Ra223 administrations was 6 (interquartile range, 5-6), and the median Ra223 completion rate was 75%. The median time from mCRPC diagnosis to Ra223 administration was 17 months, and the median number of prior treatments was 2. Multivariable analysis indicated that unfavorable performance status (>0), prostate-specific antigen (PSA) level >10 ng/ml, extension of bone metastasis score 3 to 4, and Ra223 incompletion were significantly associated with poor overall survival. In addition, EOD 3 to 4 and 3 or more prior CRPC treatments were significantly associated with Ra223 incompletion.Six-cycle completion and earlier administration of Ra233 are potentially associated with favorable survival. Unfavorable factors (EOD 3-4 and ≥3 prior treatments) were significantly associated with Ra223 incompletion.
科研通智能强力驱动
Strongly Powered by AbleSci AI